Expertise in
10
conditions

Dr. Wade L. Thorstad

Radiation Oncology
Washington University School Of Medicine
4921 Parkview Pl Lowr Level, 
Saint Louis, MO 
Accepting New Patients
Expertise in
10
conditions
Washington University School Of Medicine
4921 Parkview Pl Lowr Level, 
Saint Louis, MO 

Overview

Wade Thorstad is a Radiation Oncologist practicing medicine in Saint Louis, Missouri.

Dr. Thorstad is highly rated in 10 conditions, according to our data. His clinical expertise encompasses Head and Neck Squamous Cell Carcinoma (HNSCC), Laryngeal Cancer, Tongue Cancer, Throat Cancer, and Gastrostomy.

He is actively involved in clinical research, co-authoring 122 peer reviewed articles and participating in 12 clinical trials. Dr. Thorstad is currently accepting new patients.

Specialties

Radiation Oncology

Licenses

Radiology in MO

Hospital Affiliations

Alton Memorial Hospital
Barnes-Jewish West County Hospital
Barnes Jewish Hospital
Christian Hospital Northeast
Memorial Hospital

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Cox Health
  • EPO
  • PPO
Essence Healthcare
  • INSURANCE PLAN
  • MEDICARE MAPD
Health Alliance
  • EPO
  • HMO
  • POS
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Home State Health
  • EPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Meridian Choice
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 11 Less Insurance Carriers -

Locations

Washington University School of Medicine
4921 Parkview Pl Lowr Level, Saint Louis, MO 63110

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

12 Clinical Trials

Randomized Phase II/III Trial of Adjuvant Radiation Therapy With Cisplatin, Docetaxel-Cetuximab, or Cisplatin-Atezolizumab in Pathologic High-Risk Squamous Cell Cancer of the Head and Neck
Randomized Phase II/III Trial of Adjuvant Radiation Therapy With Cisplatin, Docetaxel-Cetuximab, or Cisplatin-Atezolizumab in Pathologic High-Risk Squamous Cell Cancer of the Head and Neck
Enrollment Status: Suspended
Publish Date: September 01, 2026
Intervention Type: Procedure, Drug, Other, Radiation, Biological
Study Drugs: Atezolizumab, Cetuximab, Cisplatin, Docetaxel
Study Phase: Phase 2/Phase 3
Immunotherapy With MK-3475 in Locoregionally Advanced, Surgically Resectable Head and Neck Squamous Cell Carcinoma
Immunotherapy With MK-3475 in Locoregionally Advanced, Surgically Resectable Head and Neck Squamous Cell Carcinoma
Enrollment Status: Completed
Publish Date: August 05, 2026
Intervention Type: Radiation, Procedure, Biological, Drug
Study Drugs: Pembrolizumab, Cisplatin
Study Phase: Phase 2
A Randomized Phase II/III Trial of De-Intensified Radiation Therapy for Patients With Early-Stage, P16-Positive, Non-Smoking Associated Oropharyngeal Cancer
A Randomized Phase II/III Trial of De-Intensified Radiation Therapy for Patients With Early-Stage, P16-Positive, Non-Smoking Associated Oropharyngeal Cancer
Enrollment Status: Active_not_recruiting
Publish Date: July 02, 2026
Intervention Type: Other, Procedure, Drug, Biological, Radiation
Study Drugs: Cisplatin, Nivolumab
Study Phase: Phase 2/Phase 3
A Randomized Phase II Trial for Patients With p16 Positive, Non-Smoking Associated, Locoregionally Advanced Oropharyngeal Cancer
A Randomized Phase II Trial for Patients With p16 Positive, Non-Smoking Associated, Locoregionally Advanced Oropharyngeal Cancer
Enrollment Status: Completed
Publish Date: May 22, 2026
Intervention Type: Drug, Radiation
Study Drug: Cisplatin
Study Phase: Phase 2
Los Tres Paso Trial: Step One - Neoadjuvant Palbociclib Monotherapy, Step Two - Concurrent Chemoradiation Therapy, and Step Three - Adjuvant Palbociclib Monotherapy in Patients With p16INK4a Negative, HPV-Unrelated Head and Neck Squamous Cell Carcinoma
Los Tres Paso Trial: Step One - Neoadjuvant Palbociclib Monotherapy, Step Two - Concurrent Chemoradiation Therapy, and Step Three - Adjuvant Palbociclib Monotherapy in Patients With p16INK4a Negative, HPV-Unrelated Head and Neck Squamous Cell Carcinoma
Enrollment Status: Active_not_recruiting
Publish Date: April 21, 2026
Intervention Type: Drug, Procedure, Radiation
Study Drugs: Palbociclib, Cetuximab, Cisplatin
Study Phase: Phase 2
Phase II Trial of Surgery Followed by Risk-Directed Post-Operative Adjuvant Therapy for HPV-Related Oropharynx Squamous Cell Carcinoma: The Minimalist Trial (MINT)
Phase II Trial of Surgery Followed by Risk-Directed Post-Operative Adjuvant Therapy for HPV-Related Oropharynx Squamous Cell Carcinoma: The Minimalist Trial (MINT)
Enrollment Status: Completed
Publish Date: April 21, 2026
Intervention Type: Other, Drug, Radiation, Procedure
Study Drug: Cisplatin
Study Phase: Phase 2
KEYSTROKE: A Randomized Phase II Study of Pembrolizumab (KEYTRUDA®) Plus Stereotactic Re-irradiation Versus SBRT Alone for Locoregionally Recurrent or Second Primary Head and Neck Carcinoma
KEYSTROKE: A Randomized Phase II Study of Pembrolizumab (KEYTRUDA®) Plus Stereotactic Re-irradiation Versus SBRT Alone for Locoregionally Recurrent or Second Primary Head and Neck Carcinoma
Enrollment Status: Active_not_recruiting
Publish Date: January 20, 2026
Intervention Type: Radiation, Drug
Study Drug: Pembrolizumab
Study Phase: Phase 2
A Phase III Study of Postoperative Radiation Therapy (IMRT) +/- Cetuximab for Locally-Advanced Resected Head and Neck Cancer
A Phase III Study of Postoperative Radiation Therapy (IMRT) +/- Cetuximab for Locally-Advanced Resected Head and Neck Cancer
Enrollment Status: Active_not_recruiting
Publish Date: January 06, 2026
Intervention Type: Biological, Radiation
Study Drug: Cetuximab
Study Phase: Phase 3
Phase II Non-Randomized Three Arm Trial of Induction Chemotherapy With Nab-Paclitaxel and Cisplatin (AP: Arms 1 and 3) or Single Agent Nab-paclitaxel (A: Arm 2) as Induction Therapy Followed by Definitive Concurrent Chemoradiation for Locally Advanced Squamous Cell Carcinoma of the Head and Neck (HNSCC): The APA Trial.
Phase II Non-Randomized Three Arm Trial of Induction Chemotherapy With Nab-Paclitaxel and Cisplatin (AP: Arms 1 and 3) or Single Agent Nab-paclitaxel (A: Arm 2) as Induction Therapy Followed by Definitive Concurrent Chemoradiation for Locally Advanced Squamous Cell Carcinoma of the Head and Neck (HNSCC): The APA Trial.
Enrollment Status: Completed
Publish Date: December 27, 2024
Intervention Type: Drug, Radiation, Biological
Study Drugs: Nab-Paclitaxel, Cisplatin, Cetuximab
Study Phase: Phase 2
Palliative Expeditiously Adaptive Quad Shot Radiation Therapy (PEAQ-RT): A Pilot Study of Consolidated Simulation and Target Identification of Quad Shot Radiation Therapy Using an Adaptive Radiotherapy Workflow With a Novel Ring Gantry Radiotherapy Device
Palliative Expeditiously Adaptive Quad Shot Radiation Therapy (PEAQ-RT): A Pilot Study of Consolidated Simulation and Target Identification of Quad Shot Radiation Therapy Using an Adaptive Radiotherapy Workflow With a Novel Ring Gantry Radiotherapy Device
Enrollment Status: Completed
Publish Date: December 08, 2023
Intervention Type: Radiation, Device
Study Phase: Not Applicable
View 9 Less Clinical Trials

121 Total Publications

High-avidity TCR signaling induces a distinct KLR-positive exhaustion state in human tumor-infiltrating CD8 T cells associated with immunotherapy response.
High-avidity TCR signaling induces a distinct KLR-positive exhaustion state in human tumor-infiltrating CD8 T cells associated with immunotherapy response.
Journal: bioRxiv : the preprint server for biology
Published: June 12, 2026
Similar Doctors
Expertise in
32
conditions
Dr. Jiayi W. Huang
Radiation Oncology
Expertise in
32
conditions
Dr. Jiayi W. Huang
Radiation Oncology
Referral may be required

Washington University School Of Medicine

4921 Parkview Pl, 
Saint Louis, MO 
 (0.9 miles away)
314-747-7236
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Jiayi Huang is a Radiation Oncologist practicing medicine in Saint Louis, Missouri. Dr. Huang is highly rated in 32 conditions, according to our data. His clinical expertise encompasses Oligodendroglioma, Astrocytoma, Glioblastoma, Tissue Biopsy, and Gamma Knife Radiosurgery. Dr. Huang is currently accepting new patients.

Expertise in
15
conditions
Dr. Perry W. Grigsby
Radiation Oncology
Expertise in
15
conditions
Dr. Perry W. Grigsby
Radiation Oncology
Referral may be required

Barnes Hospital Washington University

510 S Kingshighway Blvd, 
Saint Louis, MO 
 (0.7 miles away)
Languages Spoken:
English
See accepted insurances

Perry Grigsby is a Radiation Oncologist practicing medicine in Saint Louis, Missouri. Dr. Grigsby is highly rated in 15 conditions, according to our data. His clinical expertise encompasses Cervical Cancer, Thyroid Cancer, Papillary Thyroid Cancer, Follicular Thyroid Cancer, and Thyroidectomy.

Expertise in
26
conditions
Dr. Clifford G. Robinson
Radiation Oncology
Expertise in
26
conditions
Dr. Clifford G. Robinson
Radiation Oncology
Referral may be required

Washington University School Of Medicine

4921 Parkview Pl, 
Saint Louis, MO 
 (0.9 miles away)
314-747-7236
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Clifford Robinson is a Radiation Oncologist practicing medicine in Saint Louis, Missouri. Dr. Robinson is highly rated in 26 conditions, according to our data. His clinical expertise encompasses Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Small Cell Lung Cancer (SCLC), and Pleuropulmonary Blastoma. Dr. Robinson is currently accepting new patients.

Frequently Asked Questions about Dr. Wade L. Thorstad

How do I make an appointment with Dr. Wade L. Thorstad?

You can book an appointment with Dr. Wade L. Thorstad by calling their office at 314-747-7236. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Wade L. Thorstad a top-rated expert for Head and Neck Squamous Cell Carcinoma (HNSCC)?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Wade L. Thorstad is classified as an Elite expert for Head and Neck Squamous Cell Carcinoma (HNSCC), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Wade L. Thorstad specialize in?

While Dr. Wade L. Thorstad is a Radiation Oncology, they have specific expertise in Head and Neck Squamous Cell Carcinoma (HNSCC), Laryngeal Cancer, and Tongue Cancer. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Radiation Oncology.

Does Dr. Wade L. Thorstad participate in research or clinical trials?

Yes. Dr. Wade L. Thorstad has published 121 articles and abstracts on conditions like Head and Neck Squamous Cell Carcinoma (HNSCC). You can view a list of Dr. Wade L. Thorstad's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Wade L. Thorstad accept my insurance?

Dr. Wade L. Thorstad accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 314-747-7236 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Thorstad's expertise for a condition
ConditionClose
View All 21 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile